Genetic Medicine’s Bottleneck Has Shifted From Discovery to Delivery
Jake Becraft, CEO and co-founder of Strand Therapeutics, argues in a Tim Ferriss Founder Kitchen conversation that genetic medicine’s central bottleneck is no longer knowing what to fix, but delivering therapeutic instructions to the right cells safely, specifically, and at scale. He presents Strand’s cancer work as an early proof point for a broader platform strategy, while warning that U.S. biotech financing, clinical-trial regulation, and manufacturing infrastructure are still built for single assets rather than compounding medicine-building systems. Becraft’s case is that without faster first-in-human trials and better delivery infrastructure, many next-generation therapies will remain in labs, move overseas, or reach too few patients.
Tim Ferriss·Jun 2, 2026·26 min read
